PCN127 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED WITH CURRENTLY AVAILABLE FIRST-LINE TREATMENTS IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC RENAL CELL CARCINOMA IN THE UNITED STATES
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI